Christine M Lukacs


Affiliation: F. Hoffmann-La Roche Ltd


  1. Liao C, Hsu J, Kim Y, Hu D, Xu D, Zhang J, et al. Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy. Arthritis Res Ther. 2013;15:R146 pubmed publisher
    ..RO9021 could serve as a starting point for the development of selective SYK inhibitors for the treatment of inflammation-related and autoimmune-related disorders. ..
  2. Lukacs C, Oikonomakos N, Crowther R, Hong L, Kammlott R, Levin W, et al. The crystal structure of human muscle glycogen phosphorylase a with bound glucose and AMP: an intermediate conformation with T-state and R-state features. Proteins. 2006;63:1123-6 pubmed